Expression of Chemokine CCL28 in Ulcerative Colitis Patients
- Author:
Dong Seok LEE
1
;
Kook Lae LEE
;
Ji Bong JEONG
;
Sue SHIN
;
Su Hwan KIM
;
Ji Won KIM
Author Information
- Publication Type:Original Article
- From:Gut and Liver 2021;15(1):70-76
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background/Aims:Ulcerative colitis (UC) is an inflammatory bowel disease for which new serological markers are required. The purpose of this study was to assess the role of the mucosaassociated epithelial chemokine CCL28 in UC.
Methods:The study included 50 patients; of these, 25 were patients with UC, and 25 were healthy controls. The levels of serum CCL28 were analyzed using enzyme-linked immunosorbent assay. CCL28 expression was analyzed by immunohistochemistry (IHC) in 15 representative colon tissues biopsied based on disease activity (UC patients with severe activity, five samples;UC patients with mild activity, five samples; healthy controls, five samples).
Results:The serum CCL28 levels were remarkably higher (p<0.05) in patients with UC (median, 235.7 pg/mL; IQR, 63.8 to 117.2 pg/mL) than in healthy controls (median, 48.9, pg/mL; IQR, 35.9 to 42.0 pg/mL). However, there was no significant difference in serum CCL28 according to disease extent or activity. In contrast, IHC analysis revealed a significant difference in CCL28 consistent with disease status, disease extent, and disease activity.
Conclusions:CCL28 could be useful for diagnosing UC. However, further validations of CCL28 on disease activity and severity are needed.
